Dulaglutide is once-weekly GLP-1 receptor agonist. Dulaglutide, sold as Trulicity by Eli Lilly, is a once-weekly GLP-1 injection for type 2 diabetes. It is one of the older GLP-1 drugs that newer medicines like ecnoglutide are compared against.
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): FDA approved Sep 18, 2014 (Trulicity, BLA 125469) for type 2 diabetes. Source: FDA approves Trulicity (BLA 125469)
Evidence tier: FDA approved
Get alerts on legal status changes ->
What it is
Dulaglutide, sold as Trulicity by Eli Lilly, is a once-weekly GLP-1 injection for type 2 diabetes. It is one of the older GLP-1 drugs that newer medicines like ecnoglutide are compared against.
How it works
A GLP-1 analog fused to an antibody fragment so it lasts a week. It boosts insulin release when blood sugar is high, lowers glucagon and slows stomach emptying.
What it's researched for
Type 2 diabetes blood sugar control and cardiovascular risk reduction in type 2 diabetes.
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2014-09-18: FDA approves Trulicity (BLA 125469) (source)
Key trials and studies
- Drugs@FDA: Trulicity BLA 125469 (label and approval history)
- Ecnoglutide vs dulaglutide head-to-head (Lancet Diabetes Endocrinol 2025)
FAQ
Is dulaglutide FDA approved?
Yes, since Sep 18, 2014, for type 2 diabetes.
Is Trulicity approved for weight loss?
No. Its approval is for type 2 diabetes, not chronic weight management.
How does dulaglutide compare to semaglutide?
Both are weekly GLP-1 drugs; see each label on Drugs@FDA for approved uses.
Related peptides
- exenatide FDA status and research
- semaglutide FDA status and research
- ecnoglutide FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of Dulaglutide or other peptides. Get alerts ->
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469
- https://pubmed.ncbi.nlm.nih.gov/40854315
Editorial review - Last reviewed Oct 29, 2026